AgaMatrix, Inc. and Sanofi Announce First Glucose Meter to Directly Connect to the iPhone® and iPod® touch

Published: May 15, 2012

SALEM, N.H., May 15, 2012 /PRNewswire/ -- AgaMatrix announced today the commercial availability of the iBGStar® Blood Glucose Monitoring System in the U.S., which consists of the iBGStar® blood glucose meter and iBGStar® Diabetes Manager App. iBGStar® is the first Food and Drug Administration (FDA) cleared blood glucose meter that directly connects to the iPhone® and iPod touch®. iBGStar® was designed and developed by AgaMatrix and is being commercialized exclusively by Sanofi.

This first in class product offers accurate blood glucose monitoring and seamless integration with the iPhone® or iPod® touch. iBGStar® is available for purchase at Apple® Retail Stores and all Walgreens stores nationwide, online at, and through Diabetic Care Services.

How iBGStar® Works

When iBGStar® is directly connected to an iPhone® or iPod® touch and used with the iBGStar® Diabetes Manager App, results are presented on the Multi-Touch display quickly after monitoring.

Once data is collected, the iBGStar® Diabetes Manager App has a range of features and multiple views for analyzing glucose patterns. Visual graphs and statistics can help people record and track their glucose results, carbohydrate intake, and insulin doses. Color-coded scorecards make it easy to identify high or low blood glucose levels. Patients can share data via e-mail with caregivers and healthcare teams. The iBGStar® Diabetes Manager App is available for free from the App Store on iPhone® and iPod touch® or at

iBGStar® can also be used independently to measure blood glucose levels; results can be synchronized later to an iPhone® or iPod touch®. iBGStar® and BGStar® Blood Glucose Test Strips, are available at all Walgreens stores nationwide, online at, and through Care Services. These test strips may be covered under certain health insurance plans so individuals should check directly with their provider.

iBGStar® received the Good Design Award in 2011 for outstanding product design in the medical category from the Chicago Athenaeum of Architecture and Design and the European Centre for Architecture Art Design and Urban Studies. Additionally, iBGStar® received the red dot design award in 2011 for outstanding product design in the life science and medicine category. The red dot design award is one of the most renowned international design competitions (, with almost 14,000 entries from 68 countries in 2010 alone. Winners are considered to be the best design in the industry worldwide.

Apple®, iPhone® and iPod touch® are trademarks of Apple Inc, registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Content purchased from the iTunes Store is for personal lawful use only. Don't steal music.

For more information, visit

Important Information

The iBGStar® meter and lancing device are for single patient use. Do not share them with anyone including other family members. Do not use on multiple patients. All parts of the kit are considered biohazardous and can potentially transmit infectious diseases, even after you have performed cleaning and disinfection.

About AgaMatrix

AgaMatrix is a private company based in Salem, New Hampshire, that invents, develops, and manufactures a line of blood glucose meters, biosensors (strips), and diabetes management software. AgaMatrix's products are designed to improve the quality of diabetes care by combining world-class analytical technology with first in class mobile software solutions. AgaMatrix technology has powered over 2.5 million meters, 1.2 billion biosensors, and is available in over 20,000 retail locations. For more company information, go to:

© 2002-2011 AgaMatrix, Inc. All trademarks and/or copyrights are properties of their respective owners. iPhone, iPod and iPod touch are trademarks of Apple Inc, registered in the U.S. and other countries. App Store is a service mark of Apple Inc.

This document is part of the Site and all Content herein shall be covered by the Legal Notice found at:

SOURCE AgaMatrix

Back to news